A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Active, not recruiting · NCT05382325 · Registry updated 2026-08-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | autosomal dominant Parkinson disease 4 | Active, not recruiting | Phase 1 | 2026-08-10 | NCT05382325 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Erasmus Medisch Centrum-Medical Oncology ( Site 0036) | Rotterdam | Netherlands | 1 |
| Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035) | Amsterdam | Netherlands | 1 |
| NEXT Oncology ( Site 0001) | San Antonio | United States | 1 |
| Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) | Toronto | Canada | 1 |
| Rambam Health Care Campus-Oncology ( Site 0021) | Haifa | Israel | 1 |
| Sanford Cancer Center ( Site 0005) | Sioux Falls | United States | 1 |
| Sheba Medical Center-ONCOLOGY ( Site 0020) | Ramat Gan | Israel | 1 |
| Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037) | Utrecht | Netherlands | 1 |